Latest News & Updates
Breaking News
26 minutes ago
Simantini Singh Deo
Other trending news you may like to read
Zymeworks’ FRα-Targeting ADC ZW191 Gets FDA Fast Track Nod To Speed Development For Advanced Or Metastatic PROC Patients
Zymeworks Inc. gains FDA Fast Track designation for ZW191, an FRα-targeting ADC for advanced or metastatic platinum-resistant ovarian cancer, accelerating clinical development.
Simantini Singh Deo
Vor Bio Begins Dosing In Global Phase 3 UPSTREAM SjD Trial, Testing Telitacicept For Primary Sjögren’s Disease With No Approved Disease-Modifying Therapy
Vor Bio begins Phase 3 dosing of telitacicept in the UPSTREAM trial for primary Sjögren’s disease, targeting patients with no approved disease-modifying therapy options.
Simantini Singh Deo
Transcenta Names Christopher Hwang Head Of Global Partnerships For Its HiCB Platform
Transcenta Therapeutics appoints Christopher Hwang to lead global partnerships and out-licensing of its HiCB platform, advancing scalable biologics manufacturing and efficiency improvements.
Simantini Singh Deo
Praxis Precision Medicines Receives FDA Acceptance And Priority Review For Relutrigine NDA In SCN2A and SCN8A Developmental And Epileptic Encephalopathies
Praxis Precision Medicines secures FDA priority review for relutrigine NDA targeting SCN2A and SCN8A developmental and epileptic encephalopathies, with PDUFA set for September 2026.
Simantini Singh Deo
